logo
ENTITY

Diurnal Limited (DNL LN)

7
Analysis
Health Care • United Kingdom
Diurnal Limited engages in the research and development of products to deliver therapeutics to humans in the United Kingdom. The company targets patient needs in chronic endocrine (hormonal) diseases. Its product pipeline includes Infacort that is in Phase III clinical trial for use in the control of Adrenal Insufficiency in neonates, infants, small children, pre-pubescent children; and Chronocort, a cortisol replacement product, which is in Phase III clinical trial for the life-long treatment of congenital adrenal insufficiency and adrenal insufficiency. The company also develops native testosterone formulation for hypogonadism; and TRI4COMBI for hypothyroidism. Diurnal Limited was incorporated in 2015 and is based in Cardiff, the United Kingdom.
more
Refresh
bullish•Diurnal Limited
•22 Apr 2022 00:02•Issuer-paid

Diurnal Group - FY21 results reflect puts and takes

Diurnal’s H122 results were hindered by COVID-19 pandemic restrictions muting the benefits from the H2 CY21 Efmody launches in Germany, UK and...

Logo
Share
bullish•Diurnal Limited
•29 Sep 2021 15:26•Issuer-paid

Diurnal Group - Efmody launched in the EU and UK

Efmody (also called Chronocort), an oral long-acting formulation of hydrocortisone, has been approved in the EU and UK to treat congenital adrenal...

Logo
Share

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.35.1

x